Viridian Therapeutics, Inc. (VRDN)
Largest Insider Buys in Sector
VRDN Stock Price History Chart
VRDN Stock Performance
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. …
Insider Activity of Viridian Therapeutics, Inc.
Over the last 12 months, insiders at Viridian Therapeutics, Inc. have bought $40.62M and sold $0 worth of Viridian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viridian Therapeutics, Inc. have bought $13.52M and sold $4.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC (See Remarks) — $120M. Mahoney Stephen F. (President and CEO) — $998,524. Beetham Thomas W. (Chief Operating Officer) — $234,100.
The last purchase of 21,400 shares for transaction amount of $499,262 was made by Mahoney Stephen F. (President and CEO) on 2024‑09‑27.
List of Insider Buy and Sell Transactions, Viridian Therapeutics, Inc.
| 2024-09-27 | President and CEO | 21,400 0.0284% | $23.33 | $499,262 | -4.74% | |||
| 2024-09-27 | Chief Operating Officer | 5,000 0.0066% | $23.41 | $117,050 | -4.74% | |||
| 2024-09-13 | 1.6M 2.1285% | $18.75 | $30M | +0.50% | ||||
| 2024-01-22 | See Remarks | 476,190 0.9578% | $21.00 | $10M | -11.63% | |||
| 2023-06-16 | Sale | Chief Legal Officer | 27 <0.0001% | $28.35 | $765 | -34.59% | ||
| 2023-06-15 | Sale | Chief Legal Officer | 2,269 0.0054% | $28.02 | $63,577 | -36.35% | ||
| 2023-06-06 | Sale | Chief Legal Officer | 5,126 0.0121% | $25.02 | $128,253 | -28.09% | ||
| 2023-06-05 | Sale | Chief Legal Officer | 499 0.0012% | $25.03 | $12,490 | -27.66% | ||
| 2023-06-02 | Sale | Chief Legal Officer | 1,875 0.0044% | $24.21 | $45,394 | -25.76% | ||
| 2023-04-12 | Chief Executive Officer | 4,000 0.01% | $25.37 | $101,479 | -24.08% | |||
| 2023-03-13 | 5,500 0.0137% | $29.15 | $160,324 | -32.03% | ||||
| 2023-03-09 | Sale | General Counsel and Secretary | 29,971 0.0733% | $29.07 | $871,257 | -33.06% | ||
| 2023-02-02 | Sale | Chief Executive Officer | 50,000 0.1224% | $36.80 | $1.84M | -41.26% | ||
| 2023-01-23 | Sale | General Counsel and Secretary | 6,843 0.0169% | $35.66 | $244,021 | -37.48% | ||
| 2023-01-17 | Sale | Chief Medical Officer | 24,853 0.0607% | $37.21 | $924,780 | -40.03% | ||
| 2023-01-10 | Sale | Chief Medical Officer | 47,377 0.1162% | $35.30 | $1.67M | -35.46% | ||
| 2022-12-21 | Sale | General Counsel and Secretary | 16,326 0.0503% | $29.19 | $476,556 | -19.58% | ||
| 2022-12-16 | Sale | General Counsel and Secretary | 1,297 0.0041% | $28.44 | $36,887 | -14.53% | ||
| 2022-12-14 | Sale | General Counsel and Secretary | 15,656 0.0491% | $28.12 | $440,247 | -14.43% | ||
| 2022-11-15 | Sale | General Counsel and Secretary | 8,125 0.0244% | $22.05 | $179,156 | +8.62% |
Insider Historical Profitability
| Fairmount Funds Management LLC | 3445813 4.3501% | $19.03 | 3 | 0 | +43.22% | |
| Mahoney Stephen F. | President and CEO | 21400 0.027% | $19.03 | 1 | 0 | |
| Beetham Thomas W. | Chief Operating Officer | 6000 0.0076% | $19.03 | 1 | 0 | |
| Frazier Life Sciences Public Fund, L.P. | 10 percent owner | 1505200 1.9002% | $19.03 | 1 | 0 | +25.75% |
| Fairmount Healthcare Fund II L.P. | 1363764 1.7216% | $19.03 | 1 | 0 | +8.93% |
Institutional Investor Ownership
| Fidelity Investments | $164.86M | 14.75 | 9.42M | +23.47% | +$31.34M | 0.01 | |
| Paradigm BioCapital Advisors LP | $88.1M | 7.88 | 5.03M | +4.94% | +$4.15M | 3.2 | |
| State Street | $78.6M | 7.03 | 4.49M | +65.73% | +$31.17M | <0.01 | |
| Vr Adviser Llc | $67.99M | 6.08 | 3.88M | +<0.01% | +$840.48 | 3.3 | |
| BlackRock | $66.76M | 5.97 | 3.81M | +11.27% | +$6.76M | <0.01 |